We appreciate the efforts of the authors of the recent ‘2016 updated EULAR evidence-based recommendations for the management of gout’ and congratulate them on the publication.1 We would like to draw attention to recommendation #6: ‘For patients on urate-lowering therapy (ULT), serum urate (SUA) level should be monitored and maintained to <6 mg/dL (360 µmol/L). A lower SUA target (<5 mg/dL; 300 µmol/L) to facilitate faster dissolution of crystals is recommended for patients with severe gout (tophi, chronic arthropathy, frequent attacks) until total crystal dissolution and resolution of gout. SUA level <3 mg/dL is not recommended in the long term’. We agree with the first half of the recommendation that proposes the treat-to-target recommendations similar to that in the American College of Rheumatology 2012 gout treatment guidelines of reducing serum urate to <6.0 mg/dL in all patients with gout …

中文翻译：

---

Richette 等人的 EULAR 痛风治疗指南：尿酸和神经认知

我们感谢最近“2016 年更新的 EULAR 痛风管理循证建议”的作者所做的努力，并祝贺他们发表。1 我们想提请注意建议 #6：“对于接受降尿酸治疗的患者治疗 (ULT) 时，应监测血清尿酸 (SUA) 水平并将其维持在 <6 mg/dL (360 µmol/L)。对于重度痛风（痛风石、慢性关节病、频繁发作）的患者，建议使用较低的 SUA 目标（<5 mg/dL；300 µmol/L）以促进晶体更快溶解，直至晶体完全溶解和痛风消退。长期不推荐 SUA 水平 <3 mg/dL。